What does circulating tumor DNA (ctDNA) testing tell me about my Pancreatic Cancer

Understanding Circulating Tumor DNA (ctDNA) Testing for Pancreatic Cancer

Circulating tumor DNA testing is a blood-based test that looks for tiny fragments of DNA shed by cancer cells into your bloodstream. Let me explain what this test can and cannot tell you about your pancreatic cancer.

What ctDNA Testing Can Do

Identify Specific Mutations: According to the NCCN Guidelines for Pancreatic Cancer, one of the greatest current uses of liquid biopsies (blood-based tests) is determining whether you have a KRAS mutation and which specific type. KRAS mutations are found in approximately 87-90% of pancreatic cancers and are a major driver of the disease. Knowing your KRAS status can help guide treatment decisions.

Detect Other Important Biomarkers: ctDNA testing can identify other actionable mutations that may affect treatment options, including:

• BRCA1, BRCA2, and PALB2 mutations (related to DNA repair deficiency)
• TP53 mutations
• Other genetic alterations that may respond to targeted therapies

Monitor Treatment Response: As explained in the CancerPatientLab webinar "Novel Therapies and New Directions in Pancreas Cancer, 2024" by Dr. [removed] O'Reilly, liquid biopsies can help monitor whether your disease is progressing and potentially predict disease progression months in advance of imaging scans.

Important Limitations for Pancreatic Cancer

Lower Sensitivity Than Other Cancers: Here's a critical point: pancreatic cancer is particularly challenging for blood-based testing. According to Dr. [removed] Strickler in the webinar "Navigating Pancreatic Cancer," pancreatic cancer is a desmoplastic tumor (meaning it's surrounded by dense fibrous tissue). This dense tissue acts like a "rubber ball" around the cancer, preventing the tumor from shedding as much DNA into the bloodstream compared to other cancers like colorectal cancer.

What This Means Practically:

• A negative ctDNA test does NOT mean you don't have cancer or don't have a specific mutation
• If your ctDNA test shows "nothing detected," your doctor may still order tissue-based testing (a biopsy) to get a definitive answer
• The test is less reliable for pancreatic cancer than for other solid tumors

Timing Challenges: According to Dr. O'Reilly's 2024 webinar, even with optimal setup, getting ctDNA results can take weeks to sometimes a month or two—not always the "real-time" information doctors hope for.

How ctDNA Testing Fits Into Your Care

Best Current Use - KRAS Status: The most reliable application right now is determining your KRAS mutational status quickly. This information helps your oncologist decide which treatments might be most effective for you.

Tissue Testing Remains the Gold Standard: According to NCCN Guidelines, tumor tissue testing is still preferred for comprehensive molecular profiling. A biopsy sample provides higher quality information because it contains actual cancer cells, not just fragments of DNA in your blood.

Integrated Approach: The most comprehensive approach combines both:

• Tissue-based testing (from a biopsy) for detailed tumor profiling
• Blood-based testing (ctDNA) for quick KRAS mutation detection and monitoring

Questions to Ask Your Oncologist

1. "Should I have ctDNA testing, tissue testing, or both?" Your doctor will consider factors like whether a biopsy is feasible and how quickly you need results.

2. "If my ctDNA test is negative, does that mean I don't have [specific mutation]?" This is crucial—a negative result doesn't rule out mutations in pancreatic cancer.

3. "How will you use the ctDNA results to guide my treatment decisions?" Understanding the practical application helps you know what to expect.

4. "Will you be monitoring my ctDNA levels during treatment?" Some centers use serial ctDNA testing to track treatment response over time.

5. "What's the timeline for getting results, and how will that affect my treatment planning?" Knowing when you'll have answers helps with decision-making.

The Bigger Picture

According to Let's Win Pancreatic Cancer's research summary, circulating tumor DNA testing shows promise for:

• Understanding treatment response
• Guiding treatment strategies to overcome resistance
• Identifying molecular drivers that influence treatment

However, as Dr. O'Reilly emphasizes, this is a "rapidly evolving area" where capabilities are changing even from a couple of years ago. New tests and technologies are being developed that may improve detection rates.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.